Brought to you by:

Cell & Gene Therapy

Layoffs
Biotech

Generation Bio jettisons 90% of employees, including R&D org

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find cash to take its lipid nanoparticle tech further.
James Waldron Aug 13, 2025 5:00am
FDA
Favicon Fierce Pharma

Vinay Prasad is back at the FDA after last month's surprise ouster

Aug 9, 2025 12:22pm
pipeline pipes RD research

BioMarin drops PKU drug once seen as possible Palynziq successor

Aug 5, 2025 4:48am
coins money pennies cents

Charles River explores crowdfunding for cell and gene incubator

Aug 4, 2025 2:55pm
Monoclonal antibody orange red background 3d rendering

Allogene reports patient death tied to mAb in CAR-T pivotal trial

Aug 1, 2025 8:30am
Closeup of blue eye on black background

4DMT climbs as gene therapy patients keep jettisoning jabs

Aug 1, 2025 5:35am
More News
Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Jul 31, 2025 9:10am
Fierce Pharma

Vinay Prasad departs FDA amid controversy over gene therapy

Jul 30, 2025 9:33am

AstraZeneca drops lead TCR therapy from $200M Neogene buy

Jul 29, 2025 4:13am

Arrowhead meets $100M milestone, awaits Sarepta payment

Jul 28, 2025 3:10pm